Healthcare / BiotechnologyTaipei ExchangeTW
$25.35
+0.55 (+2.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-428.8M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-28.1%
↓Gross Margin
-24.5%
↓Debt/Equity
0.67
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.4%
FCF CAGR
—
FCF margin
-17.1%
FCF / Net income
0.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $740.2M · net income $-448.6M · FCF $-126.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $740.2M | $740.2M | $683.9M | $652.6M | $732.3M |
| Net Income | $-448.6M | $-448.6M | $-467.1M | $-682.8M | $-453.6M |
| EBITDA | $-136.1M | $-136.1M | $-136.5M | $-342.0M | $-161.1M |
| EPS | — | — | -2.27 | -3.32 | -2.74 |
| Gross Margin | -24.5% | -24.5% | -35.3% | -57.5% | -15.5% |
| Operating Margin | -54.8% | -54.8% | -67.5% | -92.4% | -56.5% |
| Net Margin | -60.6% | -60.6% | -68.3% | -104.6% | -61.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.67 | 0.67 | 0.44 | 0.30 | 0.31 |
| Current Ratio | 0.62 | 0.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-126.3M | $-126.3M | $-522.2M | $-428.8M | $-789.2M |
| Returns | |||||
| ROE | -28.1% | -28.1% | -23.1% | -27.9% | -14.6% |
| Valuation | |||||
| P/B | 3.29 | 3.29 | 4.39 | 2.97 | 1.95 |
| Growth & Yield | |||||
| Revenue Growth | 8.2% | 8.2% | 4.8% | -10.9% | — |
| EPS Growth | — | — | 31.6% | -21.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.27 → n/d
Residual
-32.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.